Related Experiment Video

Updated: May 19, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on

Teresa Jackowska1, Justyna Pluta

  • 1Department of Pediatrics, The Medical Centre of Postgraduate Education, Warsaw, Poland.

Archives of Medical Science : AMS
|August 2, 2012
PubMed

Insights

Reduced dosing schedules for pneumococcal conjugate vaccines (PCV7 and PCV13) show promise in infant immunization, potentially lowering costs and logistical issues. However, careful monitoring of immune responses is crucial.

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Pneumococcal conjugate vaccines (PCV7 and PCV13) are vital for infant immunization against pneumococcal disease.
  • Current standard schedules involve 3 primary doses plus a booster.
  • Some countries utilize a reduced 2-dose primary series with a booster.

Purpose of the Study:

  • To review evidence supporting reduced dosing schedules for PCV7 and PCV13.
  • To assess the immunogenicity and effectiveness of these alternative schedules.
  • To inform healthcare practitioners and policymakers on reduced vaccination strategies.

Main Methods:

  • Systematic review of existing clinical evidence.
  • Analysis of immunogenicity and effectiveness data for reduced dosing regimens.
  • Evaluation of cost and supply chain implications.

Main Results:

  • Evidence suggests reduced schedules can maintain immunogenicity and, in some cases, effectiveness.
  • Potential benefits include reduced costs and simplified vaccine administration.
  • Concerns exist regarding antibody responses to specific pneumococcal serotypes with reduced schedules.

Conclusions:

  • Reduced dosing schedules for PCV7 and PCV13 may offer practical advantages.
  • Further prospective surveillance is recommended for countries adopting these programs.
  • Balancing efficacy with potential immune response variations is key for policy decisions.

Keywords:
13-valent7-valentpneumococcalschedulevaccine

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...